Profile: Eagle Pharmaceuticals Inc (EGRX.A)
11 Jul 2019
Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company's product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin's lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Its bendamustine product is a lyophilized powder that requires reconstitution in water prior to use. The EP-3101 RTD and Bendeka liquid formulations eliminate the need to reconstitute the drug prior to use, relative to the lyophilized presentation of Treanda.
As of December 31, 2016, the Company focused on developing EP-3101 RTD, an RTD, multi-dose liquid with extended drug stability for use with a 500 milliliter (mL) intravenous (IV) infusion bag. Argatroban is an anti-coagulant developed for the treatment of heparin-induced thrombocytopenia (HIT). Docetaxel is an injectable oncology drug indicated for the treatment of non-small cell lung cancer, hormone refractory prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck cancer. Dantrolene is the drug approved to treat a genetic disorder called malignant hyperthermia (MH). As of December 31, 2016, the two dantrolene drugs on the market for the treatment of MH, Dantrium and Revonto, were offered in a vial containing 20 milligram (mg) of lyophilized powder that required mixing with 60 mL of sterile water. As of December 31, 2016, it was engaged in developing EP-5101 as a ready-to-use/dilute liquid form of pemetrexed available in a 25 mg/mL per vial. EP-5101 is an RTD liquid formulation of pemetrexed.
The Company competes with GlaxoSmithKline, West-Ward Pharmaceuticals, Par Pharmaceutical, Inc., US WorldMeds, Sanofi and Sandoz Inc.
Eagle Pharmaceuticals Inc
50 Tice Blvd Ste 315
WOODCLIFF LAKE NJ 07677-7637